The FDA approved pembrolizumab on May 23, 2017, for the treatment of adult and pediatric
patients with unresectable or metastatic, microsatellite instability-high (MSI-H), or mismatch …

Immunotherapy has emerged as a major therapeutic modality in oncology. Currently,
however, the majority of patients with cancer do not derive benefit from these treatments …

Advances in cancer immunity have promoted a major breakthrough in the field of cancer
therapy. This is mainly associated with the successful development of immune checkpoint …

Decades of advancements in immuno-oncology have enabled the development of current
immunotherapies, which provide long-term treatment responses in certain metastatic cancer …

Glioblastoma is the most common primary malignant brain tumour. Survival is poor and
improved treatment options are urgently needed. Although immunotherapies have emerged …

Glioma is the most common intracranial primary malignancy, with limited treatment options
and a poor overall survival (OS). Immunotherapy has been used successfully in various …

Pediatric central nervous system tumors are the most common solid malignancies in
childhood, and aggressive therapy often leads to long-term sequelae in survivors, making …

Cancer immunotherapies, widely heralded as transformational for many adult cancer
patients, are becoming viable options for selected subsets of pediatric cancer patients. Many …

Purpose: Immunotherapy promises unprecedented benefits to patients with cancer.
However, the majority of cancer types, including high-risk neuroblastoma, remain …

Immune checkpoint inhibitors (ICIs) have shown unprecedented benefits in various adult
cancers, and this success has prompted the exploration of ICI therapy even in childhood …